- Home
- ORGO vs DLY Comparison
ORGO vs DLY Comparison
Compare ORGO & DLY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ORGO
- DLY
- Stock Information
- Founded
- ORGO 1985
- DLY 2019
- Country
- ORGO United States
- DLY United States
- Employees
- ORGO N/A
- DLY N/A
- Industry
- ORGO Biotechnology: Pharmaceutical Preparations
- DLY Investment Managers
- Sector
- ORGO Health Care
- DLY Finance
- Exchange
- ORGO Nasdaq
- DLY Nasdaq
- Market Cap
- ORGO 620.3M
- DLY 744.3M
- IPO Year
- ORGO N/A
- DLY N/A
- Fundamental
- Price
- ORGO $4.92
- DLY $15.54
- Analyst Decision
- ORGO Buy
- DLY
- Analyst Count
- ORGO 2
- DLY 0
- Target Price
- ORGO $7.50
- DLY N/A
- AVG Volume (30 Days)
- ORGO 729.3K
- DLY 215.9K
- Earning Date
- ORGO 11-11-2025
- DLY 01-01-0001
- Dividend Yield
- ORGO N/A
- DLY 8.93%
- EPS Growth
- ORGO N/A
- DLY N/A
- EPS
- ORGO N/A
- DLY N/A
- Revenue
- ORGO $429,531,000.00
- DLY N/A
- Revenue This Year
- ORGO $2.57
- DLY N/A
- Revenue Next Year
- ORGO $9.80
- DLY N/A
- P/E Ratio
- ORGO N/A
- DLY N/A
- Revenue Growth
- ORGO N/A
- DLY N/A
- 52 Week Low
- ORGO $2.48
- DLY $13.26
- 52 Week High
- ORGO $6.71
- DLY $15.95
- Technical
- Relative Strength Index (RSI)
- ORGO 54.02
- DLY 54.75
- Support Level
- ORGO $4.75
- DLY $15.36
- Resistance Level
- ORGO $5.10
- DLY $15.72
- Average True Range (ATR)
- ORGO 0.21
- DLY 0.08
- MACD
- ORGO -0.01
- DLY 0.01
- Stochastic Oscillator
- ORGO 51.40
- DLY 49.58
About ORGO Organogenesis Holdings Inc.
Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerative medicine products in the advanced wound care category includes Apligraf, Dermagraft, PuraPly AM, CYGNUS Dual, etc., and the sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting. The company operates in a single segment, that is, regenerative medicine.
About DLY DoubleLine Yield Opportunities Fund of Beneficial Interest
DoubleLine Yield Opportunities Fund is a diversified, limited-term, closed-end management investment company. Its investment objective is to seek a high level of total return, with an emphasis on current income. The company invests in debt securities and other income-producing investments of issuers anywhere in the world, including in emerging markets, and may invest in investments of any credit quality. Its investment portfolio comprises foreign corporate bonds, foreign government bonds, non-agency commercial mortgage-backed obligations, U.S. corporate bonds, collateralized loan obligations, and bank loans among other securities.